Accuracy of Axillary Ultrasound in the Detection of Nodal Metastasis in Breast Cancer: Experience on 620 cases

Abstract

Purpose: Axillary lymph node status is one of the most important prognostic factors in early-stage breast cancer. Sentinel lymph node biopsy is used to determine the status of axillary nodes. There is a subset of patients in whom preoperative identification of nodal metastases could lead directly to axillary dissection. Preoperative axillary ultrasonography is a generally available noninvasive technique for assessing nodal status.

Materials and Methods: Based on retrospective data, we analyzed the sensitivity, specificity, positive and negative predictive values, and accuracy of preoperative ultrasonography performed at our institution on patients who underwent surgery for breast cancer from January 2009 to December 2010 (24 months). A total of 620 axillary ultrasonographic examinations were included, and results were compared with pathological exam.

Results: Ultrasonography revealed unremarkable findings in 500/620 (80%) axillae. There were 368 true negatives, 91 true positives, 29 false positives and 132 false negatives. Sensitivity was 40.8% and specificity 92.7%. Preoperative ultrasonography had a positive predictive value of 75.8%, and a negative predictive value of 73.6%, with an accuracy of 74.0%.

Conclusion: This sample from our institution represents one of the largest reported in the literature and shows that preoperative axillary ultrasound is a method with high specificity but relatively low sensitivity for detecting the presence of axillary metastasis.

Keywords: Axillary ultrasound; Breast cancer; Sentinel lymph node; Axillary dissection; AUS; ALND; SLNB

Synopsis

Preoperative identification of nodal metastases could lead directly to axillary dissection in a subset of patients. This large series from our institution shows that this technique has high specificity but relatively low sensitivity for detecting the presence of axillary metastasis.

Introduction

Axillary node status is one of the most important prognostic factors for breast cancer [1]. Staging based on tumor size and node status constitutes a reliable predictor of survival. Sentinel lymph node biopsy (SLNB) represents a standard for staging the axilla in early-stage breast cancer [2]. This method helps to determine the current surgical approach of the axilla in many scenarios and the number of involved nodes plays an important role in decisions for postoperative radiotherapy and systemic treatment.

For many years axillary lymph node dissection was the gold standard to determine lymph node status, but it is associated with increase morbidity and not necessarily a benefit in terms of rate of distant metastasis [3-4]. SLNB is associated with markedly fewer complications compared to complete axillary lymph node dissection (ALND) [4-5]. However, further preoperative assessment of the axilla by other methods may provide additional information to aid improving the performance of SLNB or in some instances to avoid it, sparing operating time and costs. Axillary ultrasound (AUS) represents a proven technique for preoperative assessment of axillary node status and is a cost-effective and noninvasive method [6-12].

Despite recent evidence that questions the role of axillary dissection in selected cases with positive SLNB [13]; information deriving from preoperative AUS is still useful in a subset of patients.

We present our experience with preoperative AUS for breast cancer and determine the accuracy of the procedure at our institution.

Materials and Methods

This study was based on retrospective data from patients who underwent surgery for breast cancer from January 2009 to December 2010 at Humanitas Cancer Center in Milan, Italy. Data was retrospectively collected in a database designed for the study. SLNB was performed in all cases and if positive for micro or macrometastasis, ALND was performed.
**Patient Population**

The total number of breast cancer cases operated during the study period was 1420, from which 766 had undergone a preoperative AUS within 100 days before surgery. Thirty patients were excluded due to lack of lymph node description on ultrasound report. Furthermore, 116 cases for which final histopathologic information on axillary status was not available (pNx) were also excluded. The remaining 620 cases with complete AUS and final histopathology reports were the subjects of this study.

**Ultrasoundography**

US was performed using high-frequency linear array transducer (14 MHz/5 MHz, Hitachi Logi Hi Vision Gold and Philips iU22) by five physicians with more than 5 years of experience and about 2000 cases/year by operator. Preoperative ultrasonographic examination and findings were documented on a written report for the 620 cases.

Examinations were completed using a standardized protocol performed in supine position with both hands placed behind the head, thereby externally rotating and abducting the arms. In this position, axillary structures can be well assessed. Transverse and sagittal planes were imaged.

Morphological characteristics of axillary lymph nodes were evaluated and classified as unsuspicious (negative), indeterminate or suspicious for metastasis.

Suspicious ultrasound finding for axillary metastasis included [14-19]:

A. loss of fat hilum
B. cortical thickening >3 mm
C. irregular shape
D. markedly hypoechoic cortex
E. round shape
F. increased peripheral blood flow

Lymph nodes were classified as benign if the cortex was even and measured <3 mm, indeterminate if the cortex was even but measured ≥3 mm or measured <3 mm but was focally thickened, and suspicious if the cortex was focally thickened and measured ≥3 mm or the fatty hilum was absent [20].

Lymph nodes were classified as indeterminate when only one or two of the criteria above were met, but it was considered that further evaluation was required. The size of the axillary lymph nodes has limited utility for determining the likelihood of metastatic disease and was therefore not used as a criterion [21].

**Histopathologic Examination of the Sentinel Lymph Node and Estimation of the Size of Metastases**

SLNs were serially and completely sectioned and examined intraoperatively on frozen sections or on formalin-fixed and paraffin-embedded sections. Briefly, each lymph node was carefully isolated from the surrounding fatty tissue leaving intact the nodal capsule. The node was then bisected along its major axis and both moieties were processed. Nodes less than 5 mm in thickness were processed uncinated. Fifteen pairs of adjacent 5μm sections were cut at 100-μm intervals from both lymph node halves, until the node was completely sectioned. One section of each pair was routinely stained with hematoxylin and eosin (H&E), the other section was stained for cytokeratins using the MNF116 monoclonal antibody (Dako, Glostrup, Denmark), as previously reported [22], whenever deemed necessary to assess the nature of atypical cells suspicious for malignancy seen in the corresponding H&E preparations. The original histologic slides of all positive SLNs were reviewed and the actual size of the metastases was assessed as described by others [22]. The largest axis of the metastatic nests in the plane of the tissue sections was measured histologically with an ocular micrometer, and the thickness was calculated according to the number of involved contiguous sections and to the sectioning interval between them. To avoid underestimation of the thickness of the metastases, the cutting intervals immediately preceding the first and following the last involved sections were also included. The recorded largest size corresponded to the maximum diameter in the plane of the section or to the thickness of the metastatic foci, whichever was larger. If multiple but distinct (i.e., separated by uninvolved tissue sections) metastases were identified in the same SLN, the size of the largest was recorded.

According to the size of the SLN metastases, 3 categories were devised: Isolated tumor cells (ITCs) as malignant cells in regional lymph node(s) no greater than 0.2 mm, micrometastases, greater than 0.2 mm and/or more than 200 cells, but none greater than 2.0 mm (>0.2-2 mm), and macrometastases (>2 mm).

**Statistical Analysis**

A database including ultrasonographic characteristics of the lymph nodes, definitive histologic diagnosis after SNLB and/or axillary dissection and staging among other variables was created. Lymph nodes classified as indeterminate were considered together with suspicious nodes. Data were described as number and percentage, or mean and standard deviation, where appropriate.

We calculated sensitivity, specificity, predictive values and accuracy of AUS based on final pathology reports. Patients without definitive histologic confirmation of axillary findings were excluded from the analysis. Values were recalculated after excluding in situ and pT1 lesions and only including ≥pT2 tumors. All calculations were made with Stata11 (StataCorp, 2009. Stata Statistical Software: Release 11. College Station, TX: StataCorp LP).

**Results**

From January 2009 to December 2010, 620 breast cancer cases operated at our institution had available complete reports on preoperative AUS and final histopathology results. Patient and tumor characteristics are shown on Table 1.

Mean patient age was 55.5 ± 12.1 years. Mean tumor size was 18.6 ± 12.4 mm with a range from 1 to 100 mm Table 2.

Invasive ductal carcinomas was observed in 75% (465/620) of patients, invasive lobular carcinoma in 13% (81/620), followed by other invasive types like mucinous and tubular carcinomas observed in 3.3% (21/620) and ductal carcinoma in situ in 8.5% (53/620) of cases.
Ultrasonography revealed unremarkable findings in 500/620 (80.6%) cases. The number of true negatives was 368 and of false negatives 132. From 120/620 positive axillary ultrasonographic examinations for the presence of metastasis, true positives were 91 and false positives 29. The calculated sensitivity was 40.8% and specificity 92.7%. Preoperative ultrasonography had a positive predictive value of 75.8%, a negative predictive value of 73.6%, and an accuracy of 74.0%.

Values were recalculated after excluding in situ and pT1 lesions and only including ≥pT2 tumors (N = 182). The sensitivity of AUS increased to 55.6%, specificity decreased to 87.7%, positive predictive value 87.0%, negative predictive value 57.1% and the accuracy to 68.5% (Tables 3 & 4).

Table 1: Patient and tumor characteristics of 620 breast cancer cases operated at our institution with available reports on preoperative axillary ultrasound and final histopathology.

| Characteristic                  | N = 620 (%) |
|--------------------------------|-------------|
| Age (mean, SD)                 | 55.5 ± 12.1 |
| Mean tumor size (mm)           | 18.6 ± 12.4 |
| Tumor size                     |             |
| pTx                            | 4 (0.7)     |
| pT0                            | 3 (0.5)     |
| pTis                           | 53 (8.5)    |
| pT1                            | 378 (61.0)  |
| pT2                            | 158 (25.5)  |
| pT3                            | 18 (2.8)    |
| pT4                            | 6 (1.0)     |
| Nodal status                   |             |
| pN0                            | 396 (63.8)  |
| pN1                            | 152 (24.5)  |
| pN2                            | 40 (6.5)    |
| pN3                            | 32 (5.2)    |
| Histotype                      |             |
| IDC                            | 465 (75.0)  |
| ILC                            | 81 (13.1)   |
| Other (invasive)               | 21 (3.3)    |
| DCIS                           | 53 (8.5)    |
| Grade                          |             |
| I                              | 82 (13.3)   |
| II                             | 322 (51.9)  |
| III                            | 152 (24.5)  |
| Unknown                        | 64 (10.3)   |
| Estrogen receptors             |             |
| Negative (<1%)                 | 81 (13.1)   |
| Positive (≥1%)                 | 507 (81.7)  |
| Unknown                        | 32 (5.2)    |
| Progesterone receptors         |             |
| Negative (<1%)                 | 119 (19.2)  |
| Positive (≥1%)                 | 471 (76.0)  |
| Unknown                        | 30 (4.8)    |
| HER2 status                    |             |
| Positive                       | 90 (14.5)   |
| Negative                       | 479 (77.3)  |
| Unknown                        | 51 (8.2)    |
Table 2: US results correlated with final pathology tumor size and axillary status.

| Pathologic Characteristic | Un susp (negative) | Indeterminate | Suspicious |
|---------------------------|-------------------|--------------|------------|
| N                         | 501               | 35           | 84         |
| Tumor size                |                   |              |            |
| pT0                       | 3 (0.6%)          | 0            | 0          |
| pT1                       | 330 (65.8%)       | 19 (54.3%)   | 29 (34.5%) |
| pT2                       | 101 (20.2%)       | 13 (37.1%)   | 44 (52.4%) |
| pT3                       | 9 (1.8%)          | 2 (5.7%)     | 7 (8.3%)   |
| Nodal status              |                   |              |            |
| pN0                       | 368 (73.4%)       | 17 (48.5%)   | 11 (13.1%) |
| pN1                       | 105 (21.0%)       | 14 (40.0%)   | 33 (39.3%) |
| pN2                       | 22 (4.4%)         | 3 (8.6%)     | 15 (17.8%) |
| pN3                       | 6 (1.2%)          | 1 (2.9%)     | 25 (29.8%) |

Table 3: AUS results and final pathology status.

| Pathology status | AUS result | Positive nodes | Negative nodes | Total |
|------------------|------------|----------------|----------------|-------|
| Positive         | 91 (TP)    | 29 (FP)        | 120            |
| Negative         | 132 (FN)   | 368 (TN)       | 500            |
| Total            | 223        | 397            | 620            |

Table 4: Sensitivity, Specificity, Predictive values and accuracy of AUS across reports.

| Study            | YEAR | Number of patients | Sensitivity | Specificity | PPV | NPV | Accuracy |
|------------------|------|--------------------|-------------|-------------|-----|-----|----------|
| Bruneton et al.  | 1986 | 60                 | 72.7%       | 97.3%       | na  | na  | na       |
| Bonnema et al.   | 1997 | 148                | 87%         | 56%         | na  | na  | na       |
| Rajesh et al.    | 2002 | 84                 | 74%         | 89%         | 87% | 84% | 83%      |
| Damera et al.    | 2003 | 187                | 55%         | 82%         | na  | na  | na       |
| Van Rijk et al.  | 2006 | 726                | 35%         | 82%         | na  | na  | na       |
| Nori et al.      | 2007 | 132                | 45.2%       | 86.80%      | 61.30% | 77.20% | 73.5% |
| Koehler et al.   | 2010 | 429                | 53.6%       | 75.5%       | 77.3% | 51.3% | 69.0% |
| Present study    | 2011 | 620                | 40.8%       | 92.7%       | 75.8% | 73.6% | 74.0% |

Discussion

Our study shows that the sensitivity of AUS in our institution for all breast tumor sizes and during a two-year period goes along with the lower range reported in the literature (40%) [23], whereas the specificity is high (92.7%).

There is an increasing body of literature addressing the challenge of axillary ultrasound assessment in primary breast cancer. The reported sensitivity and specificity of ultrasonography for detecting metastases in axillary lymph nodes ranges from 35% to 87% and from 55% to 97%, respectively (Table 4) [24-27]. There are many reasons for this marked heterogeneity. Some studies, like our own, utilized axillary ultrasound alone to predict nodal metastasis without the routine addition of fine needle aspiration or biopsy [24,26-32]. The involved node identification rate, where stated, was very variable; in some studies as low as 35% [27] and in others it was much higher at 53.6% [22] and even up to 87% [24]. In many studies the node identification rate is not specifically mentioned; only that absence of an abnormal

Citation: Saltarin LL, Bue GL, Garcia-Etienne CA, Morenghi E, Tommaso LD, et al. (2016) Accuracy of Axillary Ultrasound in the Detection of Nodal Metastasis in Breast Cancer: Experience on 620 cases. J Cancer Prev Curr Res 6(4): 00212. DOI: 10.15406/jcpcr.2016.06.00212
node was taken as an indication of an axilla free from metastatic disease.

Up to about fifteen years ago, preoperative staging was based only on palpation and physical examination; physical examination has low sensitivity (34–76%) [7,33] and cannot distinguish between metastatic and reactive lymph nodes [5]. Ultrasonography is now the most useful non-invasive diagnostic technique for the evaluation of axillary lymph nodes. It is widely available, and inexpensive. It causes little if any patient discomfort and provides access to all the lymph node chains. It can assess the morphological characteristics of both palpable and non-palpable lymph nodes.

In an early work that included 60 patients in 1986, Bruneton et al. [8] compared the significance of preoperative axillary ultrasonography with palpation. The authors stated that ultrasonography had a sensitivity of 72.7% and a specificity of 97.3%, whereas palpation had a sensitivity of only 45.4% and a specificity of 97.3%, i.e. a value identical to that of ultrasonography.

In 1997, Bonnema et al. [24] published a study including 148 patients. The inclusion criteria were histologically proven breast cancer and the absence of suspicious axillary lymph nodes on palpation. In this study, the sensitivity of axillary ultrasonography was 87% and its specificity was 56%.

Ultrasonography shows changes in the size and shape of lymph nodes that can reflect the presence of underlying metastases. Some authors calculate the ratio between the longitudinal and transversal diameters of the lymph node [33]. Nevertheless, the size of benign and malignant lymph nodes can be similar. Others assess the presence of Doppler flow in the hilum [15]. However, most authors agree that the morphology and cortical thickness are the most valuable parameters for determining metastatic involvement [6,16,33].

Figures published by Rajesh et al. [25] were also slightly higher than in our study, with a sensitivity of 74%, a specificity of 89%, and a positive predictive value of 87%. The examined population was quite similar to our patients regarding mean age and tumor size.

A study published by Damera et al. [26] in 2003 including 187 patients showed a sensitivity of 55% and a specificity of 82%, which is similar to our report.

In 2005, Podkrajsek et al. [34] published a study including 165 patients. Lymph nodes appearing suspicious or malignant underwent fine-needle biopsy and were cytologically examined. Ultrasound by itself had a sensitivity of 58%, its specificity was 89%.

A study by Van Rijk et al. [27] with 726 patients and the study by Nori et al. [11] with 132 cases both showed a rather low sensitivity of 35% and 45.2%, respectively, with a relatively high specificity of 82% and 86.8%; a positive predictive value of 61.3% and a negative predictive value of 77.2% with an accuracy of 73.5%.

On Table 4, the three largest reports (ours included), tend to show lower sensitivity (35-53%) for detecting lymph node metastasis compared to smaller and older series. This could be likely explained by relatively higher disease stages in older series and differences in patient selection.

After excluding in situ carcinomas and small lesions (pT1), the sensitivity of AUS was 55.6% and PPV increased. It could be assumed this would increase its cost-effectiveness, which represents an important aspect for ultrasound, as it is a time-consuming task for the operator and efforts should be made to optimize its indications.

Despite that specificity of AUS is fairly high as demonstrated in the literature [8,11,25-27,33,34] and in our study, and although there are several studies dedicated to better characterize suspicious lymph nodes [6,8,10-14,18,33,35], it seems that there is no clear or absolute reliable correlation between sonographic appearance and pathological anatomy of metastatic lymph nodes. Operator experience and methodology during ultrasound examination play an essential role when searching for suspicious axillary lymph nodes [35]. Based on these factors, AUS should be considered a separate procedure from breast ultrasound, so that experience can be evaluated individually.

Given that our study population was mostly represented by early-stage disease (approximately 70% of cases with pTis or pT1), the expected rate of axillary node involvement is quite low, as evidenced by the high proportion of cases with unremarkable findings on AUS (80%). This indicates that efforts should focus in improving patient selection for this exam. Moreover, after the advent of recent evidence that questions the benefit of ALND in patients with early-stage breast cancer who have one to two positive SLNs and who undergo breast conservation with whole breast radiotherapy, the rationale for preoperative AUS in breast cancer needs to be reformulated.

Patients with larger tumors in whom sparing ALND is not planned in advance would likely be adequate candidates for this exam. Means to assess regional nodes with less invasive methods could still provide useful information in these cases, sparing operating time and costs [36,37].

References

1. Fisher B, Bauer M, Wickerham D, Redmond CK, Fisher ER (1983) Relation of the number of positive axillary nodes to the prognosis of patient with primary breast cancer: an NSABP update. Cancer 52(9): 1551-1557.

2. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, et al. (2010) Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol 11(10): 927-933.

3. Warmuth MA, Bowen G, Prosnitz LR (1998) Complications of axillary lymph node dissection for carcinoma of the breast. Cancer 83(7): 1362-1368.

4. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, et al. (2007) Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial. Lancet Oncol 8(10): 881-888.

5. Kell MR, Burke JP, Barry M, Morrow M (2010) Outcome of axillary staging in early breast cancer: a meta-analysis. Breast Cancer Res Treat 120(2): 441-447.

6. Alvarez S, Añorbe E, Alcorta P, Lopes F, Alonso I, et al. (2006) Role
of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. AJR Am J Roentgenol 186(5): 1342-1348D.

7. Bedrosian I, Bedi D, Kuerer HM, Fornage BD, Barker L, et al. (2003) Impact of clinicopathological factors on sensitivity of axillary ultrasonography in the detection of axillary nodal metastases in patients with breast cancer. Ann Surg Oncol 10(9): 1025-1030.

8. Bruneton JN, Caramella E, Herpy M, Aubanel D, Manzino J, et al. (1986) Axillary lymph node metastases in breast cancer: preoperative detection with US. Radiology 158(2): 325-326.

9. Deurloo EE, Tanis PJ, Gilhuys KG, Muller SH, Koerger R, et al. (2003) Reduction in the number of sentinel lymph node procedures by preoperative ultrasonography of the axilla in breast cancer. Eur J Cancer 39(8): 1068-1073.

10. Hergan K, Haid A, Zimmermann G, et al. (1996) Preoperative axillary ultrasound in breast carcinoma: value of the method in routine clinical practice. Ultraschall in Med 17(1): 14-17.

11. Nori J, Yaniu E, Bazzocchi M, Bufalini FN, Disteche V, et al. (2007) Role of axillary ultrasound examination in the selection of breast cancer patients for sentinel node biopsy. Am J Surg 193(1): 16-20.

12. Strauss HG, Lamp Re, Methfessel G, Buchmann J (1998) Preoperative axilla sonography in breast tumor suspected of malignancy - a diagnostic advantage? Ultraschall in Med 19(2): 70-77.

13. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, et al. (2001) Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA 305(6): 569-575.

14. Moore A, Hester M, Nam MW, Brill YM, McGrath P, et al. (2008) Distinct lymph nodal sonographic characteristics in breast cancer patients at high risk for axillary metastases correlate with the final axillary stage. Br J Radiol 81(968): 630-636.

15. Yang WT, Chang J. Metreweli C (2000) Patients with breast cancer: differences in color Doppler flow and gray-scale US features of benign and malignant axillary lymph nodes. Radiology 215(2): 568-573.

16. Abe H, Schmidt RA, Sennett CA, Shimauchi A, Newstead GM (2007) US-guided core needle biopsy of axillary lymph nodes in patients with breast cancer: why and how to do it. Radiographics. 27(Suppl 1): S91-S99.

17. Topal U, Pansar S, Tasdelen I, Adim SB (2005) Role of ultrasound-guided core needle biopsy of axillary lymph nodes in the initial staging of breast carcinoma. Eur J Radiol 56(3): 382-385.

18. Moon HL, Kim MJ, Kim BK, Park BW, Youk JH, et al. (2009) US Surveillance of regional lymph node recurrence after breast cancer surgery. Radiology 252(3): 673-81.

19. Chung MC (2010) Axillary Ultrasound and Fine-Needle Aspiration in the Preoperative Valuation of the Breast Cancer Patient: An Algorithm Based on Tumor Size and Lymph Node Appearance. AJR Am J Roentgenol 195(5): 1261-1267.

20. Koelliker SL, Chung MA, Mainiero MB, Steinhoff MM, Cady B (2008) Axillary lymph nodes: Guided fine-needle aspiration for initial staging of breast cancer-correlation with primary tumor size. Radiology 246(1): 81-89.

21. Viale G, Bosari S, Mazzarol G, Galimberti V, Luini A, et al. (1999) Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients. Cancer 85(11): 2433-2438.

22. Viale G, Maiorano E, Mazzarol G, Zurrira S, Galimberti V, et al. (2001) Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 92(6): 1378-1384.

23. Cools-Lartigue J, Meterissian S (2012) Accuracy of axillary ultrasound in the diagnosis of nodal metastasis in invasive breast cancer: a review. World J Surg 36(1): 46-54.

24. Bonnema J, van Geel AN, van Ooijen B, Mali WP, Tijl AM, et al. (1997) Ultrasound-guided aspiration biopsy for detection of nonpalpable axillary node metastases in breast cancer patients: new diagnostic method. World J Surg 21(3): 270-274.

25. Rajesh YS, Ellenhobby S, Banerjee B (2002) Preoperative axillary ultrasound scan: its accuracy in assessing the axillary nodal status in carcinoma breast. Breast 11(1): 49-52.

26. Damara A, Evans AJ, Corndon EF, Wilson AR, Burrell HC, et al. (2003) Diagnosis of axillary nodal metastases by ultrasound-guided core biopsy in primary operable breast cancer. Br J Cancer 89(7): 1311-1313.

27. van Rijk MC, Deurloo EE, Nieweg OE, Gilhuys KG, Peterse JL, Oe et al. (2006) Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 13(1): 31-35.

28. Sato K, Tamaki K, Tsucha H, Kosuda S, Kusono S, et al. (2005) Utility of axillary ultrasound examination to select breast cancer patients suitable for optimal sentinel node biopsy. Am J Surg 187(6): 679-683.

29. Esen G, Gurses B, Yilmaz MH, Iyvan S, Ulus S, Celik V, et al. (2005) Gray scale and power Doppler US in the preoperative evaluation of axillary metastases in breast cancer patients with no palpable nodes. Eur Radiol 15(6): 1215-1223.

30. Krishnamurthy S, Sniege N, Bedi DG, Edelstein BS, Fornage BD, et al. (2002) Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast carcinoma. Cancer 95(5): 982-988.

31. Veronesi U, Galimberti V, Mariani L, Gatti G, Paganelli G, et al. (2005) Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. Eur J Cancer 41: 231-237.

32. Garcia-Ortega MJ, Benito MA, Vahamonde EF, Torres PR, Velasco AB, et al. (2011) Pretreatment axillary ultrasonography and core biopsy in patients with suspected breast cancer: diagnostic accuracy and impact on management. Eur J Radiol 79(1): 64-72.

33. Koehler KE, Oehler RE (2011) Sensitivity and Specificity of Preoperative Ultrasonography for Diagnosing Nodal Metastases in Patients with Breast Cancer: Ultraschall in Med 32(4): 393-399.

34. Podkrajsek M, Music MM, Kadic Z, Zagajnar J, Besic N, et al. (2005) Role of ultrasound in the preoperative staging of patients with breast cancer. Eur Radiol 15(5): 1044-1050.

35. Yang WT, Ahuja A, Tang A, Suen M, King W, et al. (1996) High resolution sonographic detection of axillary lymph node metastases in breast cancer. J Ultrasound Med 15(3): 241-246.

36. Bedi DG, Krishnamurthy R, Krishnamurthy S, Edelsten BS, Le-Petross H, et al. (2008) Cortical morphologic features of axillary lymph nodes as a predictor of metastasis in breast cancer: in vitro sonographic study. AJR Am J Roentgenol 191(3): 646-652.

37. Choi YJ, Ko EY, Han BK, Shin JH, Kang SS, et al. (2009) High-resolution ultrasonographic features of axillary lymph node metastases in patients with breast cancer. Breast 18(2): 119-122.